NB002 / Neologics Biosci - LARVOL DELTA

A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1a/1b | N=30 | Not yet recruiting | Sponsor: Suzhou Neologics Bioscience Co., Ltd.

Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor • HAVCR2

NB002, a novel therapeutic antibody targeting unique epitope on TIM-3 presenting potent antitumor activity (AACR 2023) - "These data could potentially explain novel features of NB002, restoring both acquired and innate immunity which could lead cold tumor to hot tumor.In summary, these data showed that NB002 is a potent anti-TIM-3 antibody with pre-clinical properties. A phase 1 study is planned and patients with advanced metastatic solid tumors will be recruited."

IO biomarker • Oncology • Solid Tumor • CTLA4 • HAVCR2 • IFNG • PD-1